Literature DB >> 8456699

MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease.

J C Chen1, P A Hardy, W Kucharczyk, M Clauberg, J G Joshi, A Vourlas, M Dhar, R M Henkelman.   

Abstract

PURPOSE: To test the hypothesis that the T2 shortening observed on MR images of the brain in patients with Parkinson and Huntington diseases is due to tissue iron deposition.
METHODS: Tissue iron and ferritin assays were performed on postmortem putamen and globus pallidus samples from subjects with Huntington and Parkinson disease. The assays were correlated with T2 measurements. Normal samples were included as controls.
RESULTS: There were significant differences in T2 values, and iron and ferritin concentrations among the putamen samples. Compared with normal controls, subjects with Huntington disease had approximately a threefold increase in iron and a sixfold increase in ferritin concentrations; however, they also had the longest T2 values. Parkinson disease putamens had milder elevations of iron concentrations above that of controls (33%) and demonstrated slightly shorter T2 values. The globus pallidus samples demonstrated a similar trend in their T2s, iron, and ferritin levels, but there was a larger overlap in the T2 values.
CONCLUSIONS: Our results indicate that tissue iron and ferritin concentrations are elevated in the brains of subjects with both Parkinson and Huntington disease but the elevated concentrations do not correlate with T2 shortening. Although iron and ferritin can shorten T2, we conclude that other factors must play a significant role in determining the T2 relaxation time and that iron or ferritin are not dominant in this regard.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456699      PMCID: PMC8332933     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  48 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

3.  Basal ganglia MR relaxometry in obsessive-compulsive disorder: T2 depends upon age of symptom onset.

Authors:  Stephen Correia; Emily Hubbard; Jason Hassenstab; Agustin Yip; Josef Vymazal; Vit Herynek; Jay Giedd; Dennis L Murphy; Benjamin D Greenberg
Journal:  Brain Imaging Behav       Date:  2009-12-12       Impact factor: 3.978

4.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

5.  Origins of R2* orientation dependence in gray and white matter.

Authors:  David A Rudko; L Martyn Klassen; Sonali N de Chickera; Joseph S Gati; Gregory A Dekaban; Ravi S Menon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-27       Impact factor: 11.205

6.  Whole brain susceptibility mapping using compressed sensing.

Authors:  Bing Wu; Wei Li; Arnaud Guidon; Chunlei Liu
Journal:  Magn Reson Med       Date:  2011-06-10       Impact factor: 4.668

7.  T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.

Authors:  Shafik N Wassef; John Wemmie; Casey P Johnson; Hans Johnson; Jane S Paulsen; Jeffrey D Long; Vincent A Magnotta
Journal:  Mov Disord       Date:  2015-03-29       Impact factor: 10.338

8.  Mineralization of the deep gray matter with age: a retrospective review with susceptibility-weighted MR imaging.

Authors:  S L Harder; K M Hopp; H Ward; H Neglio; J Gitlin; D Kido
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

9.  MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease.

Authors:  Caroline K Jurgens; Radu Jasinschi; Ahmet Ekin; Marie-Noëlle W Witjes-Ané; Huub Middelkoop; Jeroen van der Grond; Raymund A C Roos
Journal:  PLoS Curr       Date:  2010-09-08

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.